| Literature DB >> 9931343 |
J M Serratosa1, P Gómez-Garre, M E Gallardo, B Anta, D B de Bernabé, D Lindhout, P B Augustijn, C A Tassinari, R M Malafosse, M Topcu, D Grid, C Dravet, S F Berkovic, S R de Córdoba.
Abstract
Progressive myoclonus epilepsy of the Lafora type or Lafora disease (EPM2; McKusick no. 254780) is an autosomal recessive disorder characterized by epilepsy, myoclonus, progressive neurological deterioration and glycogen-like intracellular inclusion bodies (Lafora bodies). A gene for EPM2 previously has been mapped to chromosome 6q23-q25 using linkage analysis and homozygosity mapping. Here we report the positional cloning of the 6q EPM2 gene. A microdeletion within the EPM2 critical region, present inhomozygosis in an affected individual, was found to disrupt a novel gene encoding a putative protein tyrosine phosphatase (PTPase). The gene, denoted EPM2, presents alternative splicing in the 5' and 3' end regions. Mutational analysis revealed that EPM2 patients are homozygous for loss-of-function mutations in EPM2. These findings suggest that Lafora disease results from the mutational inactivation of a PTPase activity that may be important in the control of glycogen metabolism.Entities:
Mesh:
Substances:
Year: 1999 PMID: 9931343 DOI: 10.1093/hmg/8.2.345
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150